Acridine derivatives activate p53 and induce tumor cell death through bax
暂无分享,去创建一个
Ronen Marmorstein | Wafik S El-Deiry | W. El-Deiry | D. Dicker | W. Ho | R. Marmorstein | J. Winkler | Wenge Wang | Wenge Wang | William C Ho | David T Dicker | Jeffrey D Winkler | Colin MacKinnon | C. Mackinnon
[1] P. Stanhope-Baker,et al. The Wilms Tumor Suppressor-1 Target Gene Podocalyxin Is Transcriptionally Repressed by p53* , 2004, Journal of Biological Chemistry.
[2] W. Denny,et al. Dual topoisomerase I/II inhibitors in cancer therapy. , 2003, Current topics in medicinal chemistry.
[3] Yoichi Taya,et al. DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.
[4] E. Stavridi,et al. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[5] K. Vousden,et al. Stress Signals Utilize Multiple Pathways To Stabilize p53 , 2000, Molecular and Cellular Biology.
[6] W. El-Deiry,et al. The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis , 2002, Cancer biology & therapy.
[7] K. Kinzler,et al. p53 tagged sites from human genomic DNA. , 1994, Human molecular genetics.
[8] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[9] Shengyun Fang,et al. Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53* , 2000, The Journal of Biological Chemistry.
[10] P. Herrlich,et al. DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation , 1999, Oncogene.
[11] Michael Weller,et al. Predicting response to cancer chemotherapy: the role of p53 , 1998, Cell and Tissue Research.
[12] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[13] R Montesano,et al. Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.
[14] M. Blagosklonny. Loss of function and p53 protein stabilization , 1997, Oncogene.
[15] D. Durocher,et al. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? , 2001, Current opinion in cell biology.
[16] R. Honda,et al. Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 , 1999, The EMBO journal.
[17] W. El-Deiry,et al. Cell cycle control as a basis for cancer drug development (Review). , 2000, International journal of oncology.
[18] D. Meek,et al. Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. , 2001, The Biochemical journal.
[19] L. Latonen,et al. UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts , 2001, Oncogene.
[20] J. Lucci,et al. A Phase II Trial of Pyrazoloacridine (PZA) in Squamous Carcinoma of the Cervix – A Gynecologic Oncology Group Study , 2001, Investigational New Drugs.
[21] M. Demma,et al. CP-31398 Restores DNA-binding Activity to Mutant p53 in Vitro but Does Not Affect p53 Homologs p63 and p73* , 2004, Journal of Biological Chemistry.
[22] T. Unger,et al. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2 , 1999, The EMBO journal.
[23] G. Stark,et al. Phosphorylation of serines 15 and 37 is necessary for efficient accumulation of p53 following irradiation with UV , 2001, Oncogene.
[24] F. Charmantray,et al. Interest of acridine derivatives in the anticancer chemotherapy. , 2001, Current pharmaceutical design.
[25] F. Zindy,et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] C. Maki,et al. The MDM2 RING-finger domain is required to promote p53 nuclear export , 2000, Nature Cell Biology.
[27] C. Maki,et al. MDM2-dependent ubiquitination of nuclear and cytoplasmic P53 , 2000, Oncogene.
[28] D. V. Hoff,et al. m-AMSA and PALA: Two new agents in cancer chemotherapy , 2004, Cancer Chemotherapy and Pharmacology.
[29] M. Blagosklonny,et al. P53: An ubiquitous target of anticancer drugs , 2002, International journal of cancer.
[30] A. Barberis,et al. CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity , 2004, Journal of Negative Results in Biomedicine.
[31] P. Howley,et al. In vivo ubiquitination and proteasome-mediated degradation of p53(1). , 1996, Cancer research.
[32] D. Lacombe,et al. Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer* , 2003, Investigational New Drugs.
[33] W. El-Deiry,et al. Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding , 2003, Molecular and Cellular Biology.
[34] B. Foster,et al. Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.
[35] W. el-Deiry,et al. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling , 2001, Cell Death and Differentiation.
[36] K. Parang,et al. Current targets for anticancer drug discovery. , 2003, Current drug targets.
[37] D. Lane,et al. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. , 2001, Experimental cell research.
[38] F. Valea,et al. A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study , 2002, Cancer Chemotherapy and Pharmacology.
[39] Wafik S El-Deiry,et al. Bioluminescent Molecular Imaging of Endogenous and Exogenous p53-Mediated Transcription In Vitro and In Vivo Using an HCT116 Human Colon Carcinoma Xenograft Model , 2003, Cancer biology & therapy.
[40] Galina Selivanova,et al. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells , 2002, Oncogene.
[41] W. Denny,et al. Acridine derivatives as chemotherapeutic agents. , 2002, Current medicinal chemistry.